Clinical Trial

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is aim to evaluate the safety and immunogenicity of one dose TetraFluvac TF vaccine (15 μg HA per strain per dose) of the GPO seasonal quadrivalent inactivated split virion influenza vaccine in healthy adults aged 18 years and above over 90 days post-injection.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-05-30; most recent amendment 2024-10-07.
Status change: Recruiting → Active, Not Recruiting 2024-01-03
Status change: Not Yet Recruiting → Recruiting 2023-12-11
Trial Details
NCT Number NCT05895955
Lead Sponsor Mahidol University
Collaborators: The Government Pharmaceutical Organization
Conditions Influenza
Enrollment 290 participants
Start Date 2023-11-04
Primary Completion 2024-03-25 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-09